"
Team:Brown
From 2009.igem.org
Every year, over fifty million people in the US suffer from allergic rhinitis, the most common type of allergy. Allergens such as pollen, dust, and dander result in nasal congestion, itching, burning, sneezing, and overall discomfort. Current treatments include over-the-counter antihistamines, however, side effects of these drugs include drowsiness, restlessness, and poor concentration. For patients suffering from chronic allergies and inflammation, there is a great need for an alternative strategy for combating allergic symptoms without causing significant side effects.
The 2009 Brown University iGEM team worked to treat allergic rhinitis by engineering Staphylococcus epidermidis, a microbe endogenous to the human nasal flora, to secrete a recombinant histamine-binding protein in response to the elevated histamine concentrations of an allergic response. The engineered strain of S. epidermidis will function as a self-regulating drug factory in the nose, providing relief, without any negative side effects.
 |
 |
 |
 |
 |
 |
&npsbLearn more about Allergene: a synthetically engineered, self-regulating drug factory in the nose. | |||
 |
&npsbWhen an allergic response occurs, our system senses a change in histamine levels above threshold and initiates an intracellular cascade, signaling cells to respond appropriately to the increase in histamine concentration. | |||
 |
&npsbThe chassis of choice for production and secretion of the Histamine Binding Protein is Staphyloccocus Epidermidis, an organism endogenous to the human nasal flora. A quorum sensing mechanism was also incorporated to regulate cell density. | |||
 |
&npsbEV131 is a high-affinity histamine binding protein, that originates from the saliva of a female tick species. | |||
 |
&npsbDescription of the overall construct'' | |||
A special thank you to Team Heidelberg for inspiring our wiki design!
